INCANDO THERAPEUTICS PARTICIPATES IN PANEL DISCUSSION AT PRESTIGIOUS 24th HONG KONG FORUM
Dr. Charles Hu, Co-Founder of Incando Therapeutics Pte. Limited (“Incando”), joined other leading business minds earlier this week in a wide-ranging discussion on the future of healthcare innovation and investment in Hong Kong. The 24th Hong Kong Forum, hosted by the Hong Kong Trade Development Council (“HKTDC”), is the flagship event of Federation of Hong Kong Business Associations Worldwide, which represents over 11,000 business executives in 36 countries worldwide. The event was well-attended by prominent Hong Kong government leadership, and business leaders from around the globe.
INCANDO THERAPEUTICS CELEBRATES RECEIPT OF PRESTIGIOUS ENTREPRENEURSHIP AWARD IN GREATER BAY AREA
Incando Therapeutics celebrates our co-founder, Dr. Charles Hu, who has recently been presented with the prestigious 2023 Guangdong-Hong Kong-Macao Greater Bay Area Outstanding Young Entrepreneur Award for Best Sci-Tech Innovation on 27th September, 2023. This award demonstrates Incando’s important role in the Guangdong-Hong Kong-Macao Greater Bay Area (“GBA”) life sciences community…
DR. CHARLES HU OF INCANDO THERAPEUTICS EMCEES OPENING CEREMONY BIOHK 2022
Dec. 18, 2022 – Incando Co-Founder Organizes and Moderates International 4-Day Biotech Convention in Hong Kong Dr. Hu moderating the opening ceremony of BioHK 2022. The event was live-streamed online and had thousands of viewers in HK, China, and globally.
INCANDO THERAPEUTICS COLLABORATES WITH JOHNS HOPKINS MEDICINE TO EXPLORE POTENTIAL FOR NEW PHOTOMEDICINE PARKINSON’S TREATMENT
Dec. 2, 2022 – Incando Therapeutics announced the launch of a collaboration study with the Johns Hopkins University to test Photobiomodulation Therapy in a Parkinson’s Disease Preclinical Mouse Model.
Incando Therapeutics 